



## REMARKS

As required by 37 C.F.R. 1.125(b) Applicants have enclosed a substitute specification in response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/or Amino Acid Sequence Disclosures, mailed September 23, 2003. As to the substitute specification, Applicants submit that no new matter was added. In the substitute specification, Applicants have inserted all the appropriate sequence identification numbers. No new matter was added.

Enclosed is the substitute Sequence Listing on CD-R, duplicate copy, and the substitute CRF copy of the sequence listing. The substitute Sequence Listing on CD-R, duplicate, and the CRF copy submitted herewith, in accordance with 37 C.F.R. § 1.825(a) and (b), respectively, are the same and contain no new matter. Accordingly, entry of the substitute Sequence Listing into the above-captioned case is respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket no. 511582002420. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: February 23, 2004

By:

Kate H. Murashige  
Registration No. (29,959)

Morrison & Foerster LLP  
3811 Valley Centre Drive  
Suite 500  
San Diego, California 92130-2332  
Telephone: (858) 720-5112  
Facsimile: (858) 720-5125